Table 6.
Characteristics and biomarker analysis of IAR with or without imaging lesions who did not undergo surgery.
| Parameter | IAR with Imaging Lesions (n = 51) |
IAR without Imaging Lesions (n = 51) |
Controls (n = 20) |
p-Value IAR with Lesions vs. IAR without Lesions |
|---|---|---|---|---|
| Gender (male/female) | 23/28 | 22/29 | 11/9 | p = 1.0 |
| Age, years, median (range) | 52 (30 to 74) | 46 (27 to 63) | 47 (21 to 71) | p = 0.0006 |
| BMI, mean ± SD | 25.8 ± 3.6 | 25.0 ± 4.3 | 23.6 ± 1.9 | p = 1.0 |
| Smoking history | 19% (9/47) | 32% (14/43) | 25% (5/20) | p = 0.157 |
| Diabetes | 4.2% (2/48) | 4.3% (2/46) | 5% (1/20) | p = 1.0 |
| History of pancreatitis | 4.2% (2/48) | 4.3% (2/46) | 0% (0/20) | p = 1.0 |
| miR-196b elevated * | 46/51 (90%) | 10/51 (20%) | 0/20 | p < 0.0001 |
| LCN2 elevated * | 34/51 (67%) | 17/51 (33%) | 0/20 | p = 0.0014 |
| TIMP1 elevated * | 19/51 (37%) | 14/51 (27%) | 0/20 | p = 0.397 |
| crExosGlypican-1 enriched * | 29/51 (57%) | 26/50 (52%) | 7/10 (70%) | p = 0.691 |
| CA 19-9 elevated * | 2/51 (3.9%) | 1/51 (2%) | 0/3 | NS |
| miR-196b + LCN2 + TIMP1 elevated * | 19/51 (37%) | 4/51 (8%) | 0/20 | p = 0.0007 |
| KRAS mutated in duodenal juice | 27/51 (53%) | 9/51 (17%) | 0/20 | p = 0.0004 |
| crExos Glypican-1 enriched in duodenal juice | 20/20 (100%) | 15/17 (88%) | 3/3 | p = 0.204 |
| KRAS mutated in duodenal juice + miR196b/LCN2/TIMP1 elevated | 8/51 (16%) | 0/51 (0%) | 0/20 | p = 0.0058 |
*, as determined in blood, bold, statistically significant, mut., mutation, IAR, individual at risk, BMI, body-mass-index, NS, not significant.